New drug telitacicept tested for MS Flare-Ups
NCT ID NCT04625153
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested telitacicept (RC18) in 8 people with relapsing-remitting multiple sclerosis. The drug aims to reduce relapses by targeting B cells. The study was terminated early, so we have limited data on safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- telitacicept (RC18)
- What this could lead to
- If it works, this could point toward a new treatment option for relapsing-remitting multiple sclerosis by targeting B cells to reduce flare-ups.
- What could go wrong
- This trial was terminated early with only 8 participants, so results are very limited. It is a phase 2 study, meaning it is still early and may not prove effective or safe in larger groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the Third Affiliated Hospital,Sun Yat-Sen University
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentle electric zap to the brain restore memory in MS?
- Brain scans may reveal how MS drug affects mental fatigue
- Brain scans could reveal which MS drugs fight mental exhaustion
- Brain shrinkage as a crystal ball for MS progression?
- Can a Once-a-Month shot tame MS relapses?
- Can MS treatments protect the mind as well as the body?